èšåºæ®µéã®éºäŒåæ²»çäŒæ¥ã§ãã Adverum Biotechnologies, Inc. ã¯ãçŒçŸæ£ããã³åžå°çŸæ£ãæ²»çããããã®éºäŒåæ²»ç補ååè£ãéçºããŠããŸãããã®äž»å補ååè£ã¯ ADVM-022 ã§ã滲åºåå éœ¢é»æå€æ§çãç³å°¿ç
é»ææµ®è
«ãªã©ã®æ
¢æ§ç¶²èçŸæ£ã®æ£è
ã®æ²»çã«äœ¿çšãããååç¡åäœå
泚å°éºäŒåæ²»çåè£ã§ããAdverum Biotechnologies, Inc. ã¯ãã«ãªãã©ã«ãã¢å€§åŠãã³ãŒãã«å€§åŠãGenSightãLexeoãããã³ Virovek ãšã©ã€ã»ã³ã¹å¥çŽããã³ååå¥çŽãçµãã§ããŸããå瀟ã¯ä»¥å㯠Avalanche Biotechnologies, Inc. ãšããŠç¥ãããŠããŸãããã2016 幎 5 æã« Adverum Biotechnologies, Inc. ã«ç€Ÿåã倿ŽããŸãããAdverum Biotechnologies, Inc. 㯠2006 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ã¬ãããŠããã·ãã£ã«æ¬ç€Ÿã眮ããŠããŸãã